SCHEMBL1102768

SCHEMBL1102768

c1ccc(N2c3ccccc3Sc3ccc(-c4c5ccccc5c(-c5ccc6c(c5)N(c5ccccc5)c5ccccc5S6)c5cnccc45)cc32)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.37
GRIN1 Q05586 4/20 0.37
GRIN2A Q12879 4/20 0.37
HDAC6 Q9UBN7 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
DYRK1A Q13627 2/20 0.33
MAPT P10636 2/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
GAA P10253 1/20 0.31
IDO1 P14902 1/20 0.31
GSK3B P49841 1/20 0.31
KCNH2 Q12809 1/20 0.31
MAOA P21397 1/20 0.30
LMNA P02545 1/20 0.30
MAPK1 P28482 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
NOX1 Q9Y5S8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102691 0.86 DYRK1A (0.36) ACHESMN1; SMN2CYP1A2CYP3A4CYP2D6
SCHEMBL1102925 0.84 HDAC6 (0.34) HDAC6
SCHEMBL1103347 0.81 HDAC6 (0.32) HDAC6
SCHEMBL1102556 0.81 DYRK1A (0.33) DYRK1AGSK3BKCNH2CDK4CCND1
SCHEMBL1102524 0.80 CDK8 (0.34) ACHESMN1; SMN2CYP1A2CYP3A4CYP2D6
SCHEMBL1102692 0.80 ADRA2A (0.37) CYP1A2CYP3A4CYP2D6DYRK1AGAA
SCHEMBL1102623 0.79 DYRK1A (0.32) DYRK1A
SCHEMBL1102548 0.78 ALDH1A1 (0.36) CYP1A2CYP3A4CYP2D6DYRK1ALMNA
SCHEMBL1102658 0.77 ACHE (0.40) ACHEGRIN1GRIN2AHDAC6SMN1; SMN2
SCHEMBL1102955 0.76 CYP17A1 (0.39) ACHEGRIN1GRIN2ASMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 ACHE 1080/4885GRIN1 3646/4885GRIN2A 3636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.